<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Eye Res</journal-id><journal-id journal-id-type="iso-abbrev">Exp. Eye Res.</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Experimental eye research</journal-title></journal-title-group><issn pub-type="ppub">0014-4835</issn><issn pub-type="epub">1096-0007</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5924632</article-id><article-id pub-id-type="pmcid-ver">PMC5924632.1</article-id><article-id pub-id-type="pmcaid">5924632</article-id><article-id pub-id-type="pmcaiid">5924632</article-id><article-id pub-id-type="manuscript-id">NIHMS945351</article-id><article-id pub-id-type="pmid">29452108</article-id><article-id pub-id-type="doi">10.1016/j.exer.2018.02.009</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS945351</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA945351</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effect of brimonidine, an &#945;2 adrenergic agonist, on human meibomian gland epithelial cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="X">Xi</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yang</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kam</surname><given-names initials="WR">Wendy R.</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sullivan</surname><given-names initials="DA">David A.</given-names></name><degrees>MS, PhD</degrees><xref ref-type="aff" rid="A1">a</xref></contrib></contrib-group><aff id="A1">
<label>a</label>Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA</aff><aff id="A2">
<label>b</label>Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</aff><author-notes><corresp id="FN1"><bold>Correspondence Address:</bold> David A. Sullivan, MS, PhD, FARVO, Schepens Eye Research Institute, 20 Staniford Street, Boston, MA, USA 02114, TEL: 617-912-0288, <email>david.sullivan@schepens.harvard.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2018</year></pub-date><volume>170</volume><issue-id pub-id-type="pmc-issue-id">311576</issue-id><fpage>20</fpage><lpage>28</lpage><pub-history><event event-type="nihms-submitted"><date><day>05</day><month>03</month><year>2018</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-18 02:25:12.620"><day>18</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms945351.pdf"/><abstract><p id="P1">We recently discovered that the anti-glaucoma pharmaceuticals timolol, a &#946; adrenergic antagonist, and pilocarpine, a cholinergic compound, negatively influence the morphology, proliferative capacity and survival of human meibomian gland epithelial cells (HMGECs). We hypothesize that another class of anti-glaucoma drugs, the &#945;2 adrenergic agonists, also acts directly on HMGECs to affect their structure and function. We tested this hypothesis. Immortalized (i) HMGECs were cultured with brimonidine, as well as clonidine (&#945;2 agonist), phenylephrine (&#945;1 agonist), RX821002 (inverse &#945;2 agonist) and MK912 (neutral &#945;2 agonist) for up to 7 days. Cells were counted with a hemocytometer, and evaluated for morphology, signaling pathway activity, protein biomarker expression, and the accumulation of neutral lipids, phospholipids and lysosomes. Our findings demonstrate that brimondine treatment induces a dose-dependent decrease in Akt signaling and proliferation of iHMGECs. In contrast, brimonidine also promotes a dose-dependent differentiation of iHMGECs, including an increase in neutral lipid, phospholipid and lysosome levels. These effects were paralleled by an inhibition of p38 signaling, and duplicated by cellular exposure to clonidine, but not phenylephrine. Brimonidine also enhanced the cellular content of sterol regulatory binding protein-1, a master regulator of lipid synthesis. Of particular interest, the putative &#945;2 antagonists, RX821002 and MK912, did not interfere with brimonidine action, but rather stimulated IHMGEC differentiation. Our results support our hypothesis and demonstrate that &#945;2 adrenergic agonists act directly on iHMGECs. However, these compounds do not elicit an overall negative effect. Rather, the &#945;2 agonists promote the differentiation of iHMGECs.</p></abstract><kwd-group><kwd>brimonidine</kwd><kwd>phospholipidosis</kwd><kwd>&#945;2 adrenergic agonist</kwd><kwd>&#945;2 adrenergic antagonist</kwd><kwd>meibomian gland dysfunction</kwd><kwd>dry eye disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>